Roivant Sciences Stock Analysis
ROIV Stock | USD 10.79 0.18 1.64% |
Roivant Sciences is fairly valued with Real Value of 10.96 and Target Price of 16.14. The main objective of Roivant Sciences stock analysis is to determine its intrinsic value, which is an estimate of what Roivant Sciences is worth, separate from its market price. There are two main types of Roivant Sciences' stock analysis: fundamental analysis and technical analysis.
The Roivant Sciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Roivant Sciences is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Roivant Stock trading window is adjusted to America/New York timezone.
Roivant |
Roivant Stock Analysis Notes
About 28.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.48. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Roivant Sciences recorded a loss per share of 1.0. The entity had not issued any dividends in recent years. Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom. Roivant Sciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 863 people. To find out more about Roivant Sciences contact Matthew Gline at 44 20 7400 3347 or learn more at https://roivant.com.Roivant Sciences Quarterly Total Revenue |
|
Roivant Sciences Investment Alerts
Roivant Sciences generated a negative expected return over the last 90 days | |
Roivant Sciences currently holds about 1.94 B in cash with (765.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
Over 80.0% of the company shares are owned by institutional investors | |
Latest headline from gurufocus.com: Roivant Sciences Ltd Announces Upcoming Investor Webcast on Immunovants Clinical Study ... |
Roivant Sciences Upcoming and Recent Events
12th of February 2024 Upcoming Quarterly Report | View | |
26th of June 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
26th of June 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of March 2023 Last Financial Announcement | View |
Roivant Largest EPS Surprises
Earnings surprises can significantly impact Roivant Sciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2025-02-11 | 2024-12-31 | -0.24 | -0.1988 | 0.0412 | 17 | ||
2022-06-28 | 2022-03-31 | -0.32 | -0.27 | 0.05 | 15 | ||
2024-11-12 | 2024-09-30 | -0.26 | -0.313 | -0.053 | 20 |
Roivant Sciences Environmental, Social, and Governance (ESG) Scores
Roivant Sciences' ESG score is a quantitative measure that evaluates Roivant Sciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Roivant Sciences' operations that may have significant financial implications and affect Roivant Sciences' stock price as well as guide investors towards more socially responsible investments.
Roivant Stock Institutional Investors
Shares | Amvescap Plc. | 2024-12-31 | 9.5 M | Geode Capital Management, Llc | 2024-12-31 | 7.8 M | Woodline Partners Lp | 2024-12-31 | 6.1 M | Toms Capital Investment Management Lp | 2024-12-31 | 5.9 M | Adage Capital Partners Gp Llc | 2024-12-31 | 5.7 M | Ubs Group Ag | 2024-12-31 | 5.3 M | Anchorage Advisors, Llc | 2024-12-31 | 4.8 M | Norges Bank | 2024-12-31 | 4.4 M | Blackbarn Capital Partners Lp | 2024-12-31 | 4.1 M | Qvt Financial Lp | 2024-12-31 | 65.8 M | Sb Investment Advisers (uk) Ltd | 2024-12-31 | 62.1 M |
Roivant Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.7 B.Roivant Profitablity
The company has Profit Margin (PM) of (0.95) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (29.22) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $29.22.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.55 | 0.58 | |
Return On Capital Employed | 0.55 | 0.58 | |
Return On Assets | 0.54 | 0.57 | |
Return On Equity | 0.84 | 0.88 |
Management Efficiency
Roivant Sciences has return on total asset (ROA) of (0.1162) % which means that it has lost $0.1162 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1464) %, meaning that it created substantial loss on money invested by shareholders. Roivant Sciences' management efficiency ratios could be used to measure how well Roivant Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.58 in 2025. Return On Capital Employed is likely to climb to 0.58 in 2025. At this time, Roivant Sciences' Return On Assets are fairly stable compared to the past year. Asset Turnover is likely to climb to 0.02 in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 32.7 M in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 9.47 | 5.83 | |
Tangible Book Value Per Share | 9.27 | 5.75 | |
Enterprise Value Over EBITDA | 0.45 | 0.47 | |
Price Book Value Ratio | 1.23 | 2.04 | |
Enterprise Value Multiple | 0.45 | 0.47 | |
Price Fair Value | 1.23 | 2.04 | |
Enterprise Value | 1.9 B | 2.1 B |
The operational strategies employed by Roivant Sciences management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Technical Drivers
As of the 23rd of March, Roivant Sciences holds the Risk Adjusted Performance of (0.05), variance of 3.83, and Coefficient Of Variation of (1,609). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Roivant Sciences, as well as the relationship between them. Please check Roivant Sciences variance and skewness to decide if Roivant Sciences is priced some-what accurately, providing market reflects its current price of 10.79 per share. Given that Roivant Sciences has information ratio of (0.03), we recommend you to check out Roivant Sciences's recent market performance to make sure the company can sustain itself at a future point.Roivant Sciences Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Roivant Sciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Roivant Sciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Roivant Sciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Roivant Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Roivant Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Roivant Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Roivant Sciences Predictive Daily Indicators
Roivant Sciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Roivant Sciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Roivant Sciences Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 19th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
25th of February 2025 Other Reports | ViewVerify | |
F4 | 24th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 21st of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
18th of February 2025 Other Reports | ViewVerify | |
14th of February 2025 Other Reports | ViewVerify |
Roivant Sciences Forecast Models
Roivant Sciences' time-series forecasting models are one of many Roivant Sciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Roivant Sciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Roivant Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Roivant Sciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Roivant shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Roivant Sciences. By using and applying Roivant Stock analysis, traders can create a robust methodology for identifying Roivant entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 30.68 | 32.21 | |
Operating Profit Margin | 30.59 | 32.12 | |
Net Profit Margin | 31.36 | 32.93 | |
Gross Profit Margin | 0.89 | 0.95 |
Current Roivant Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Roivant analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Roivant analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
16.14 | Strong Buy | 10 | Odds |
Most Roivant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Roivant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Roivant Sciences, talking to its executives and customers, or listening to Roivant conference calls.
Roivant Stock Analysis Indicators
Roivant Sciences stock analysis indicators help investors evaluate how Roivant Sciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Roivant Sciences shares will generate the highest return on investment. By understating and applying Roivant Sciences stock analysis, traders can identify Roivant Sciences position entry and exit signals to maximize returns.
Begin Period Cash Flow | 1.7 B | |
Long Term Debt | 430.6 M | |
Common Stock Shares Outstanding | 831 M | |
Total Stockholder Equity | 6 B | |
Tax Provision | 22.2 M | |
Quarterly Earnings Growth Y O Y | -0.961 | |
Property Plant And Equipment Net | 66 M | |
Cash And Short Term Investments | 6.5 B | |
Cash | 6.5 B | |
Accounts Payable | 53.2 M | |
Net Debt | -6 B | |
50 Day M A | 10.783 | |
Total Current Liabilities | 266.8 M | |
Other Operating Expenses | -4.1 B | |
Non Current Assets Total | 490.7 M | |
Non Currrent Assets Other | 39.1 M | |
Stock Based Compensation | 199.6 M |
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.